Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04353271 · ClinicalTrials.gov registry record · Phase 2
Trial of Hydroxychloroquine In Covid-19 Kinetics
A Phase 2 study, sponsored by University of South Alabama.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04353271: Clinical Trial Phase 2 study, sponsored by University of South Alabama.
NCT04353271 is a Phase 2 study that was terminated before completion, run by University of South Alabama. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04353271, a Phase 2 study, was terminated before completion, sponsored by University of South Alabama.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
To test if the medication Hydroxychloroquine will decrease the amount of virus(as measured by PCR) , 7 days after initiation of therapy compared to control patients receiving placebo. The study design is a randomized (5 days of medication v. 5 days of placebo) clinical trial initiated immediately after diagnosis in ambulatory health care workers at University of South Alabama Health, or in ambulatory USA patients. At 7 days after enrollment another nasopharyngeal swab will be taken to measure if the virus is still present. At 10 weeks we will measure immunity from Covid-19 using a single blood sample. It is a phase 2/3 clinical trial.
Interventions
- OTHER Placebo
- DRUG Hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-04-17 |
| Est. Completion | 2020-07-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04353271
The ClinicalTrials.gov registry entry for NCT04353271 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Alabama, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04353271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04353271 about?
NCT04353271 is a clinical study titled "Trial of Hydroxychloroquine In Covid-19 Kinetics". To test if the medication Hydroxychloroquine will decrease the amount of virus(as measured by PCR) , 7 days after initiation of therapy compared to control patients receiving placebo. The study design is a randomized (5 days of medication v. 5 days of placebo) clinical trial initiated immediately a...
What is the current status of trial NCT04353271?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2020-04-17. Estimated completion is 2020-07-08.
What interventions are being tested in trial NCT04353271?
The interventions under investigation include: Placebo (OTHER), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT04353271?
This trial is sponsored by University of South Alabama, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.